Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course

Melanie Schirmer, Lee Denson, Hera Vlamakis, Eric A. Franzosa, Sonia Thomas, Nathan M. Gotman, Paul Rufo, Susan S. Baker, Cary Sauer, James Markowitz, Marian Pfefferkorn, Maria Oliva-Hemker, Joel Rosh, Anthony Otley, Brendan Boyle, David Mack, Robert Baldassano, David Keljo, Neal LeLeiko, Melvin Heyman & 8 others Anne Griffiths, Ashish S. Patel, Joshua Noe, Subra Kugathasan, Thomas Walters, Curtis Huttenhower, Jeffrey Hyams, Ramnik J. Xavier

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT (Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients were monitored for 1 year upon treatment initiation, and microbial taxonomic composition was analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of bacteria typical of the oral cavity were associated with baseline disease severity. Remission and refractory disease were linked to species-specific temporal changes that may be implicative of therapy efficacy, and a pronounced increase in microbiome variability was observed prior to colectomy. Finally, microbial associations with disease-associated serological markers suggest host-microbial interactions in UC. These insights will help improve existing treatments and develop therapeutic approaches guiding optimal medical care. Many patients exhibit incomplete responses to ulcerative colitis (UC) therapy. Schirmer et al. investigate the gut microbiome's role in pediatric UC treated with two conventional therapies. Baseline and longitudinal microbial trends are implicated in disease severity and progression, including remission and colectomy requirement. These insights may motivate new therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)600-610.e4
JournalCell Host and Microbe
Volume24
Issue number4
DOIs
StatePublished - Oct 10 2018

Fingerprint

Ulcerative Colitis
Therapeutics
Colectomy
Gastrointestinal Microbiome
Pediatric ulcerative colitis
Microbial Interactions
Microbiota
Colitis
Mouth
Disease Progression
Pediatrics
Bacteria
Biopsy

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Microbiology
  • Virology

Cite this

Schirmer, M., Denson, L., Vlamakis, H., Franzosa, E. A., Thomas, S., Gotman, N. M., ... Xavier, R. J. (2018). Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host and Microbe, 24(4), 600-610.e4. https://doi.org/10.1016/j.chom.2018.09.009
Schirmer, Melanie ; Denson, Lee ; Vlamakis, Hera ; Franzosa, Eric A. ; Thomas, Sonia ; Gotman, Nathan M. ; Rufo, Paul ; Baker, Susan S. ; Sauer, Cary ; Markowitz, James ; Pfefferkorn, Marian ; Oliva-Hemker, Maria ; Rosh, Joel ; Otley, Anthony ; Boyle, Brendan ; Mack, David ; Baldassano, Robert ; Keljo, David ; LeLeiko, Neal ; Heyman, Melvin ; Griffiths, Anne ; Patel, Ashish S. ; Noe, Joshua ; Kugathasan, Subra ; Walters, Thomas ; Huttenhower, Curtis ; Hyams, Jeffrey ; Xavier, Ramnik J. / Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. In: Cell Host and Microbe. 2018 ; Vol. 24, No. 4. pp. 600-610.e4.
@article{9ef3ef1dbaff41bc980177947bdc5b23,
title = "Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course",
abstract = "Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT (Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients were monitored for 1 year upon treatment initiation, and microbial taxonomic composition was analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of bacteria typical of the oral cavity were associated with baseline disease severity. Remission and refractory disease were linked to species-specific temporal changes that may be implicative of therapy efficacy, and a pronounced increase in microbiome variability was observed prior to colectomy. Finally, microbial associations with disease-associated serological markers suggest host-microbial interactions in UC. These insights will help improve existing treatments and develop therapeutic approaches guiding optimal medical care. Many patients exhibit incomplete responses to ulcerative colitis (UC) therapy. Schirmer et al. investigate the gut microbiome's role in pediatric UC treated with two conventional therapies. Baseline and longitudinal microbial trends are implicated in disease severity and progression, including remission and colectomy requirement. These insights may motivate new therapeutic approaches.",
author = "Melanie Schirmer and Lee Denson and Hera Vlamakis and Franzosa, {Eric A.} and Sonia Thomas and Gotman, {Nathan M.} and Paul Rufo and Baker, {Susan S.} and Cary Sauer and James Markowitz and Marian Pfefferkorn and Maria Oliva-Hemker and Joel Rosh and Anthony Otley and Brendan Boyle and David Mack and Robert Baldassano and David Keljo and Neal LeLeiko and Melvin Heyman and Anne Griffiths and Patel, {Ashish S.} and Joshua Noe and Subra Kugathasan and Thomas Walters and Curtis Huttenhower and Jeffrey Hyams and Xavier, {Ramnik J.}",
year = "2018",
month = "10",
day = "10",
doi = "10.1016/j.chom.2018.09.009",
language = "English (US)",
volume = "24",
pages = "600--610.e4",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "4",

}

Schirmer, M, Denson, L, Vlamakis, H, Franzosa, EA, Thomas, S, Gotman, NM, Rufo, P, Baker, SS, Sauer, C, Markowitz, J, Pfefferkorn, M, Oliva-Hemker, M, Rosh, J, Otley, A, Boyle, B, Mack, D, Baldassano, R, Keljo, D, LeLeiko, N, Heyman, M, Griffiths, A, Patel, AS, Noe, J, Kugathasan, S, Walters, T, Huttenhower, C, Hyams, J & Xavier, RJ 2018, 'Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course', Cell Host and Microbe, vol. 24, no. 4, pp. 600-610.e4. https://doi.org/10.1016/j.chom.2018.09.009

Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. / Schirmer, Melanie; Denson, Lee; Vlamakis, Hera; Franzosa, Eric A.; Thomas, Sonia; Gotman, Nathan M.; Rufo, Paul; Baker, Susan S.; Sauer, Cary; Markowitz, James; Pfefferkorn, Marian; Oliva-Hemker, Maria; Rosh, Joel; Otley, Anthony; Boyle, Brendan; Mack, David; Baldassano, Robert; Keljo, David; LeLeiko, Neal; Heyman, Melvin; Griffiths, Anne; Patel, Ashish S.; Noe, Joshua; Kugathasan, Subra; Walters, Thomas; Huttenhower, Curtis; Hyams, Jeffrey; Xavier, Ramnik J.

In: Cell Host and Microbe, Vol. 24, No. 4, 10.10.2018, p. 600-610.e4.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course

AU - Schirmer, Melanie

AU - Denson, Lee

AU - Vlamakis, Hera

AU - Franzosa, Eric A.

AU - Thomas, Sonia

AU - Gotman, Nathan M.

AU - Rufo, Paul

AU - Baker, Susan S.

AU - Sauer, Cary

AU - Markowitz, James

AU - Pfefferkorn, Marian

AU - Oliva-Hemker, Maria

AU - Rosh, Joel

AU - Otley, Anthony

AU - Boyle, Brendan

AU - Mack, David

AU - Baldassano, Robert

AU - Keljo, David

AU - LeLeiko, Neal

AU - Heyman, Melvin

AU - Griffiths, Anne

AU - Patel, Ashish S.

AU - Noe, Joshua

AU - Kugathasan, Subra

AU - Walters, Thomas

AU - Huttenhower, Curtis

AU - Hyams, Jeffrey

AU - Xavier, Ramnik J.

PY - 2018/10/10

Y1 - 2018/10/10

N2 - Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT (Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients were monitored for 1 year upon treatment initiation, and microbial taxonomic composition was analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of bacteria typical of the oral cavity were associated with baseline disease severity. Remission and refractory disease were linked to species-specific temporal changes that may be implicative of therapy efficacy, and a pronounced increase in microbiome variability was observed prior to colectomy. Finally, microbial associations with disease-associated serological markers suggest host-microbial interactions in UC. These insights will help improve existing treatments and develop therapeutic approaches guiding optimal medical care. Many patients exhibit incomplete responses to ulcerative colitis (UC) therapy. Schirmer et al. investigate the gut microbiome's role in pediatric UC treated with two conventional therapies. Baseline and longitudinal microbial trends are implicated in disease severity and progression, including remission and colectomy requirement. These insights may motivate new therapeutic approaches.

AB - Evaluating progression risk and determining optimal therapy for ulcerative colitis (UC) is challenging as many patients exhibit incomplete responses to treatment. As part of the PROTECT (Predicting Response to Standardized Colitis Therapy) Study, we evaluated the role of the gut microbiome in disease course for 405 pediatric, new-onset, treatment-naive UC patients. Patients were monitored for 1 year upon treatment initiation, and microbial taxonomic composition was analyzed from fecal samples and rectal biopsies. Depletion of core gut microbes and expansion of bacteria typical of the oral cavity were associated with baseline disease severity. Remission and refractory disease were linked to species-specific temporal changes that may be implicative of therapy efficacy, and a pronounced increase in microbiome variability was observed prior to colectomy. Finally, microbial associations with disease-associated serological markers suggest host-microbial interactions in UC. These insights will help improve existing treatments and develop therapeutic approaches guiding optimal medical care. Many patients exhibit incomplete responses to ulcerative colitis (UC) therapy. Schirmer et al. investigate the gut microbiome's role in pediatric UC treated with two conventional therapies. Baseline and longitudinal microbial trends are implicated in disease severity and progression, including remission and colectomy requirement. These insights may motivate new therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=85054102370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054102370&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2018.09.009

DO - 10.1016/j.chom.2018.09.009

M3 - Article

VL - 24

SP - 600-610.e4

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 4

ER -